Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694821 · ClinicalTrials.gov registry record · Phase 4
Knee Injection RCT
A Phase 4 study, sponsored by UConn Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
NCT03694821 is a Phase 4 study that was terminated before completion, run by UConn Health. The registered enrollment target is 18 participants.
The verdict
NCT03694821, a Phase 4 study, was terminated before completion, sponsored by UConn Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
Study Summary
Hypothesis: Ketorolac injection is a cost-effective adjunct in the nonoperative treatment of knee osteoarthritis (OA) compared to steroids and viscosupplementation. Aims/objectives: The objective of this randomized, controlled, double-blinded, prospective study is to assess the efficacy and cost-effectiveness of knee injection with ketorolac in the nonsurgical management of symptomatic OA compared to injections with corticosteroids and viscosupplements.
Interventions
- DRUG Ketorolac Tromethamine Injection
- DRUG Methylprednisolone Acetate Injection
- DRUG Hylan G-F 20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-07-05 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03694821
The ClinicalTrials.gov registry entry for NCT03694821 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ketorolac Tromethamine Injection is the first listed.
NCT03694821 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03694821 about?
NCT03694821 is a clinical study titled "Knee Injection RCT". Hypothesis: Ketorolac injection is a cost-effective adjunct in the nonoperative treatment of knee osteoarthritis (OA) compared to steroids and viscosupplementation. Aims/objectives: The objective of this randomized, controlled, double-blinded, prospective study is to assess the efficacy and cost-ef...
What is the current status of trial NCT03694821?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2018-07-05. Estimated completion is 2019-07-16.
What interventions are being tested in trial NCT03694821?
The interventions under investigation include: Ketorolac Tromethamine Injection (DRUG), Methylprednisolone Acetate Injection (DRUG), Hylan G-F 20 (DRUG).
Who is sponsoring clinical trial NCT03694821?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.